Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scientific Inc. reports developments tied to computerized drug delivery instruments for dental and medical applications. The company’s Dynamic Pressure Sensing technology supports pressure-guided injection and fluid-aspiration procedures, including dental anesthesia delivery through The Wand STA system and medical applications such as CompuFlo for controlled epidural injections.
Recurring news themes include financial results, business-update calls, commercialization programs, physician and dental-practice adoption, distributor and reimbursement infrastructure, international product registrations, disposable utilization, operating expense initiatives, and capital actions involving common stock and warrants.
Milestone Scientific Inc. (NYSE:MLSS) will host a conference call on May 17, 2022, at 8:30 AM ET to discuss its financial results for Q1 2022, ending March 31. The call aims to provide insights into the company's corporate progress and developments. U.S. callers can join by calling toll-free 888-506-0062, and international callers can reach +1 973-528-0011. An audio replay will be available until May 31, 2022. Milestone Scientific specializes in innovative injection technologies, enhancing patient comfort and safety.
Milestone Scientific (NYSE:MLSS) announced that its President and CEO, Arjan Haverhals, will present at the Noble Capital Markets Eighteenth Annual Investor Conference on April 21, 2022, at 11:30 am ET in Seminole Ballroom D. Investors can meet management at breakout sessions on April 20. A video webcast of the presentation will be available the following day on the company’s website and other platforms for 90 days. Milestone specializes in advanced drug delivery systems, enhancing patient comfort and safety through innovative technologies.
Milestone Scientific Inc. (NYSE: MLSS) has formed a strategic partnership with Keystone Dental Group to enhance the distribution of its STA Single Tooth Anesthesia® system in the dental implant market. This collaboration leverages Keystone's sales force of over 60 representatives to expand reach into surgical specialties. Additionally, Milestone has partnered with American Independent Dental Alliance to access over 1,000 dental practices, and with Esthetic Professionals to enhance dental education through hands-on training. These initiatives aim to drive growth in the expanding DSO market.
Milestone Scientific (NYSE: MLSS) has begun sales of its CompuFlo Epidural and CathCheck Verification System to a leading medical center recognized as one of the World’s Best Hospitals-USA for four consecutive years. The approval comes after a successful evaluation and emphasizes the systems' clinical advantages in improving accuracy and reducing complication rates during epidural procedures. These innovations aim to drive better health outcomes at lower costs, with potential economic benefits for healthcare institutions.
Milestone Scientific (NYSE: MLSS) reported a remarkable 90% year-over-year revenue growth for 2021, totaling $10.3 million, surpassing previous guidance and pre-pandemic levels. The company highlights strong dental division performance and profitability with high gross margins. Expansion in medical distribution includes new partnerships with pain management clinics and hospitals. Despite challenges from the pandemic, particularly in labor and delivery departments, Milestone is optimistic about regaining momentum. The company holds a robust cash position of $14.8 million to fuel growth initiatives.
Milestone Scientific (NYSE:MLSS) has announced a conference call set for April 1, 2022, at 8:30 AM ET to discuss its financial results for the fiscal year ending December 31, 2021. The call will cover corporate progress and developments. Investors can join via telephone or access a webcast on the company’s Investor Relations page. An audio replay will be available until April 15, 2022. Milestone Scientific specializes in computerized drug delivery instruments aimed at providing painless and precise injections, enhancing patient comfort and safety.
Milestone Scientific (NYSE:MLSS) has launched sales of its CompuFlo Epidural disposables at two California surgery centers: Cypress and Galileo. Both facilities, owned by Pain Management Specialists, will utilize Milestone's technology to enhance patient care. CEO Arjan Haverhals noted that this expansion follows successful evaluations of the system's safety and economic efficiency. Milestone is focused on developing advanced drug delivery systems to improve injection precision, comfort, and safety.
Milestone Scientific Inc. (NYSE: MLSS) is set to participate in The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Conference from February 8-11, 2022. CEO Arjan Haverhals will present on February 9 at 10:30 AM ET. The presentation can be accessed via webcast on the company's website. The conference includes 25-minute virtual presentations and one-on-one meetings for investors. This event showcases qualified institutional investors' best ideas.
Milestone Scientific (NYSE: MLSS) announced that CEO Arjan Haverhals will participate in a virtual fireside chat on January 20, 2022, hosted by Maxim Group's Anthony Vendetti. This event aims to provide insights into Milestone's advanced computerized drug delivery technology, which ensures painless and precise injections. Investors can view the live webcast at 11:00 a.m. EST, with a replay available for 48 hours afterward. Milestone is focused on enhancing patient comfort and safety through its innovative DPS Dynamic Pressure Sensing Technology®.
Milestone Scientific (NYSE: MLSS) reports anticipated revenues over $2.6 million for Q4 2021, up from $2.2 million in Q4 2020, and over $10 million for FY 2021, a significant increase from $5.4 million in FY 2020. CEO Arjan Haverhals highlights growth in dental and medical divisions, with successful marketing efforts and new distributors contributing to an 85% revenue increase. The company expresses confidence in its future, citing a strong balance sheet and a substantial market opportunity in the U.S. for epidural analgesia, estimated at over $5 billion annually.